Sparks commentary

Healthcare

Sparks

Oncoinvent (OSE: ONCIN) advances Radspherin after Phase II safety review
Published by Arron Aatkar, PhD

Oncoinvent has reported encouraging interim safety data for Radspherin, its targeted radiation therapy administered into the abdomen following surgery for advanced ovarian cancer. Of the 74 patients randomised by 30 October, 56 were included in the safety analysis, comprising 40 receiving Radspherin and 16 receiving standard care alone. No serious adverse events were considered possibly related to Radspherin, and there were no deaths or treatment discontinuations due to adverse events. Five Radspherin recipients (12.5%) experienced 10 possibly related adverse events, all mild or moderate, while the overall incidence of adverse events was similar between the treatment groups. Encouragingly, following its review, the independent monitoring committee recommended that the trial continue without modification.

The findings reinforce Radspherin’s favourable safety profile observed in earlier trials and support Oncoinvent’s preparations for Phase III development. Radspherin aims to eliminate microscopic cancer deposits remaining after surgery, although its ability to delay disease progression remains to be established in a randomised setting. The next important catalyst is the interim efficacy readout expected in April 2027, with Phase II recruitment scheduled for completion in the first half of 2027.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.